Montelukast as an Add-on Drug in Induced Azotemia in Humans Following Gastroenteritis

Background: Gastroenteritis, as a rare and heterogeneous condition, is characterized by patchy or diffuse infiltration of gastrointestinal tissue. Induced azotemia in humans following gastroenteritis has been evaluated in some studies. Objectives: The aim of present study was to evaluate the effect of montelukast on induced azotemia in humans following gastroenteritis. Methods: This study examined children with gastroenteritis with moderate dehydration and more than 3 years of age. The cases had a glomerular filtration rate (GFR) less than 90 and were evaluated in two groups of control (n = 20) and intervention (n = 20). Montelukast (5-mg tablets) was given to patients in the intervention group for 5 days. Normal saline at a rate of 20 cc/kg was given to both groups within 20 minutes until clinical symptoms improved. Finally, the improvement of renal function was evaluated and compared between the 2 groups using SPSS. Results: Out of 40 evaluated patients, the mean age of the control and intervention groups was 5.52 and 5.15 years, respectively. Also, 13 cases (65.0%) in the control group and 9 cases (45.0%) in the control group were males. The mean creatinine (Cr) was significantly reduced after treatment in the intervention group (P = 0.001). Also, the mean GFR after treatment was significantly higher in the intervention group (P = 0.001), and GFR improvement duration was significantly lower in the intervention group (P = 0.002). Conclusions: Montelukast as an add-on drug was effective in reducing the time of GFR enhancement; thus, we can consider it as an add-on drug in azotemia.